NEWS

Combining machine learning tools for medical imaging with genetic sequencing nets Sophia Genetics $110M

October 1, 2020

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics added another $110 million to its coffers in a series F financing led by aMoon and Hitachi Ventures.

Read More

Venture capitalists find more to Israel than Zionism

September 30, 2020

Not all olim arrive in Israel to serve in the IDF or go to university. In the case of two aMoon executives, coming to Israel was a way to advance their careers in venture capital health investments while also reaching the goal of living in the Jewish state.

Read More

Adicet Announces Completion of Merger with resTORbio

September 15, 2020

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc

Read More

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing

September 15, 2020

Seer, Inc., an aMoon2 portfolio company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc.

Read More

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

September 10, 2020

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund.

Read More

MOBILion Closes $35M Series B Financing Round

August 17, 2020

aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery

Read More

Roche invests millions in Israel’s health tech sector

August 11, 2020

has entered into a partnership agreement with aMoon, an Israeli venture capital company focused on health technology and science. The “StarFinder Lab” collaboration is aiming to help young startups develop innovative diagnostic tools to tackle global health care challenges.

Read More

Israel’s Largest Health VC Boosts Fund to $750 Million on Virus

July 22, 2020

Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.

Read More

Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics

July 15, 2020

Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.

Read More

Israel Bolsters Antibody Tests as Second Virus Wave Threatens

July 3, 2020

Israel is fortifying its national survey of exposure to the coronavirus as a second wave of infections threatens to plunge the country back into lockdown.

Read More

Pharma Two B Doses First Patients in Early-stage Parkinson’s Phase 3 Trial

February 12, 2018

Israel’s Pharma Two B has dosed the first patients in a Phase 3 trial to evaluate the safety and efficacy of its drug candidate P2B001 to treat early-stage Parkinson’s disease.

Read More

Additional Strategic Funding for CartiHeal’s Ongoing AGILI-C™ IDE Clinical Study

January 31, 2018

KFAR SABA, Israel & DURHAM, N.C.–(BUSINESS WIRE)–CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured a $2.5M investment from Bioventus, a global leader in orthobiologics – reflecting the growing interest in CartiHeal’s technology.

Read More

Pharma Two B Ltd. Closes $30 Million Financing Round

January 23, 2018

REHOVOTH, Israel, Feb. 27, 2017 /PRNewswire/ — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it has completed its third round of financing. The $30MM funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and…

Read More

Marius Nacht to invest $20m in Regenera

January 2, 2018

aMoon Partners, controlled and managed by by Check Point Software Technologies Ltd. (Nasdaq: CHKP) cofounder Marius Nacht, together with Dr. Yair Schindel, is likely to invest $20 million more in pharma company Regenera, in which InterCure Ltd. (TASE: INCR-L) owns a 23.48% stake. According to the proposal, aMoon will invest $10 million now and $10 million more as needed.

Read More

Nacht, Harel Insurance invest in personalized cancer treatment

December 7, 2017

Ayala Pharmaceuticals has bought rights from international company Bristol-Myers Squibb (BMS) to develop a personalized treatment for cancer. Ayala, founded a few months ago for this purpose, is an initiative by the Israel Biotech Fund, led by Dr. David Sidransky, Dr. Yuval Cabilly, and Ido Zairi. The fund recruited the aMoon Partners fund (led by Check…

Read More

Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

December 6, 2017

REHOVOT, Israel–(BUSINESS WIRE)–Ayala Pharmaceuticals, a biopharmaceutical company dedicated to developing targeted cancer therapies, announced today that they have entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for two gamma secretase inhibitors in development for the treatment of cancers with altered Notch genes.

Read More

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

August 17, 2017

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science ventures, founded by Marius Nacht and Dr. Yair Schindel.

Read More

CartiHeal raises $18.3m to support PMA trial of Agili-C implant

May 8, 2017

CartiHeal said today it raised $18.3 million in a new round of financing to support an FDA IDE-approved clinical trial of its Agili-C implant for use in repairing cartilage and osteochondral defects.

Read More

Israeli Universal Flu Vaccine Maker Receives $2.8 Million Investment

January 4, 2017

Israeli billionaire Marius Nacht is banking on Israeli bio-tech with a $2.8 million investment into BiondVax Pharmaceuticals, a clinical phase company developing a universal flu vaccine.

Read More